Balchem Q2 Sales Surge 11%, Crushing Estimates Across All Segments
BCPC sits 17% above its 52-week low of $139.17.
Summary
Balchem delivered a broad-based beat in Q2, with sales jumping 11% to $284M against a $268.5M consensus and adjusted EPS of $1.49 topping the $1.40 estimate. All three segments—Human Nutrition, Animal Nutrition, and Specialty Products—hit record sales and earnings, signaling strong demand across the portfolio. The company also bought back $29M in stock and expanded its credit facility to $650M, adding financial flexibility. This follows a quiet period with no major news since the credit agreement amendment in late July. The stock trades at 27x forward earnings, down from 30x three months ago, leaving room for multiple expansion if momentum continues.
At the time of this announcement, BCPC was trading at $163.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2B. The 52-week trading range was $139.17 to $183.90. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.